Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
DDLS
MCID: DDF001
MIFTS: 49

Dedifferentiated Liposarcoma (DDLS)

Categories: Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Dedifferentiated Liposarcoma

About this section

MalaCards integrated aliases for Dedifferentiated Liposarcoma:

Name: Dedifferentiated Liposarcoma 12 58 15 17
Liposarcoma, Dedifferentiated 71
Liposarcoma Dedifferentiated 54
Ddls 58

Characteristics:

Orphanet epidemiological data:

58
dedifferentiated liposarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0080531
NCIt 50 C3704
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0205824
Orphanet 58 ORPHA99970
UMLS 71 C0205824
Sources

Summaries for Dedifferentiated Liposarcoma

About this section
Disease Ontology : 12 A liposarcoma that is characterized as a high-grade tumor that occurs when a lower-grade tumor changes and creates new high-grade cells.

MalaCards based summary : Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to fibrous histiocytoma and pleomorphic lipoma. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Trabectedin and Didanosine have been mentioned in the context of this disorder. Affiliated tissues include colon, breast and lymph node, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Dedifferentiated Liposarcoma

About this section

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 422)
# Related Disease Score Top Affiliating Genes
1 fibrous histiocytoma 31.7 KIT DES CD34
2 pleomorphic lipoma 31.5 MDM2 HMGA2 CDK4 CD34
3 well-differentiated liposarcoma 31.4 TP53 MYOG MDM2 KIT HMGA2 FRS2
4 malignant fibrous histiocytoma 31.3 TP53 MYOG MDM2 MB KIT DES
5 spindle cell sarcoma 31.2 MYOG MDM2 KIT DES CD34
6 osteogenic sarcoma 31.1 TP53 RB1 MDM2 IGF1R CDKN2A CDK4
7 pleomorphic liposarcoma 31.1 MDM2 KIT DES DDIT3 CDKN2A CDK4
8 sclerosing liposarcoma 31.0 MDM2 CD34
9 lipomatosis, multiple 31.0 PTEN NF1 MDM2 KIT HMGA2 DES
10 myxoid liposarcoma 30.9 TP53 MDM2 IGF1R HMGA2 DDIT3 CDK4
11 liposarcoma 30.9 TP53 STAT6 RB1 PTEN PPARG NF1
12 embryonal sarcoma 30.9 TP53 MYOG MDM2 KIT DES CDK4
13 retroperitoneal sarcoma 30.9 MYOG MDM2 KIT CDK4 CD34
14 mesenchymal cell neoplasm 30.9 TP53 MYOG KIT HMGA2 CD34
15 myxofibrosarcoma 30.9 TP53 MYOG MET MDM2 KIT DES
16 spindle cell liposarcoma 30.9 MDM2 DDIT3 CDK4 CD34
17 mixed liposarcoma 30.9 MDM2 DDIT3 CDK4 CD34
18 sarcoma 30.8 TP53 RB1 MYOG MDM2 KIT DDIT3
19 inflammatory myofibroblastic tumor 30.8 TP53 RB1 MDM2 KIT DES CDK4
20 malignant mesenchymoma 30.7 MYOG MDM2 MB DES CD34
21 mediastinum liposarcoma 30.7 MDM2 CDKN2A CDK4
22 pseudosarcomatous fibromatosis 30.7 MYOG KIT DES CD34
23 inflammatory liposarcoma 30.7 MDM2 CDKN2A CD34
24 extraosseous osteosarcoma 30.7 MDM2 CDK4 CD34
25 cellular myxoid liposarcoma 30.7 MDM2 DDIT3 CDK4
26 connective tissue benign neoplasm 30.7 TP53 MDM2 KIT CDK4 CD34
27 embryonal rhabdomyosarcoma 30.7 TP53 MYOG MDM2 MB DES CDK4
28 gallbladder sarcoma 30.7 MYOG DES
29 intravenous leiomyomatosis 30.6 HMGA2 DES CD34
30 infiltrating lipoma 30.6 MDM2 HMGA2 CDK4 CD34
31 follicular dendritic cell sarcoma 30.5 KIT CDKN2A CD34
32 heart sarcoma 30.5 MYOG MDM2 KIT CD34
33 neurilemmoma 30.5 NF1 KIT DES CD34
34 ring chromosome 30.5 TP53 MDM2 IGF1R HMGA2 CDK4
35 meningioma, familial 30.5 TP53 PTEN NF1 CDKN2A CD34
36 kidney cancer 30.5 TP53 PTEN MET CDKN2A
37 spindle cell lipoma 30.5 RB1 MDM2 DES CDK4 CD34
38 sarcomatoid carcinoma 30.5 MYOG MB KIT DES
39 gastrointestinal stromal tumor 30.4 TP53 PTEN NF1 KIT DES CDKN2A
40 retroperitoneal leiomyosarcoma 30.4 KIT CD34
41 leiomyosarcoma 30.4 TP53 RB1 NF1 MYOG MDM2 MB
42 myoma 30.4 TP53 KIT HMGA2 CD34
43 b-lymphoblastic leukemia/lymphoma 30.3 RB1 KIT CDKN2A CD34
44 lynch syndrome 30.3 TP53 RB1 PTEN MDM2 DES CDKN2A
45 li-fraumeni syndrome 30.2 TP53 RB1 PTEN NF1 MDM2 CDKN2A
46 retinoblastoma 30.2 TP53 RB1 PPARG MYOG MET MDM2
47 type 2 diabetes mellitus 30.1 TP53 PTEN PPARG IGF1R DDIT3 CDKN2A
48 malignant peripheral nerve sheath tumor 30.1 TP53 NF1 MYOG MET MDM2 KIT
49 rhabdomyosarcoma 30.1 TP53 RB1 PTEN NF1 MYOG MET
50 adenocarcinoma 29.9 TP53 RB1 PTEN MET MDM2 KIT

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:



Diseases related to Dedifferentiated Liposarcoma
Sources

Symptoms & Phenotypes for Dedifferentiated Liposarcoma

About this section

GenomeRNAi Phenotypes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.28 CDKN2A IGF1R KIT NF1 PPARG
2 Decreased viability GR00221-A-2 10.28 IGF1R NF1 PPARG
3 Decreased viability GR00221-A-3 10.28 CDKN2A IGF1R PPARG
4 Decreased viability GR00221-A-4 10.28 CDKN2A NF1 PPARG
5 Decreased viability GR00249-S 10.28 NF1
6 Decreased viability GR00301-A 10.28 IGF1R KIT
7 Decreased viability GR00342-S-2 10.28 IGF1R
8 Decreased viability GR00386-A-1 10.28 NF1 PPARG
9 Decreased viability GR00402-S-2 10.28 IGF1R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.09 MDM2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.09 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.09 MDM2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.09 IGF1R MDM2 STAT6
14 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.09 RB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.09 RB1 STAT6
16 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.09 RB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.09 STAT6
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.09 RB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.09 MDM2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-33 10.09 STAT6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.09 STAT6
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.09 MDM2 RB1 STAT6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-48 10.09 CEBPA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.09 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.09 STAT6
26 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.09 IGF1R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.09 MDM2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-72 10.09 CEBPA STAT6
29 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.09 STAT6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.09 IGF1R
31 Decreased substrate adherent cell growth GR00193-A-1 10.06 IGF1R KIT MET
32 Decreased substrate adherent cell growth GR00193-A-2 10.06 CDK4 KIT
33 Decreased substrate adherent cell growth GR00193-A-3 10.06 CDK4 MET
34 Decreased substrate adherent cell growth GR00193-A-4 10.06 CDK4 IGF1R KIT MET
35 Decreased sensitivity to paclitaxel GR00112-A-0 9.37 NF1 PTEN
36 Reduced mammosphere formation GR00396-S 9.32 CD34 CDK4 CEBPA DDIT3 DES FRS2
37 Decreased viability in glioblastoma multiforme (GBM) lineage; decreased viability in pancreas lineage GR00235-A 8.85 PPARG

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 CD34 CDK4 CDKN2A CEBPA DDIT3 DES
2 behavior/neurological MP:0005386 10.54 CDK4 CDKN2A CEBPA DDIT3 DES IGF1R
3 cardiovascular system MP:0005385 10.53 CDK4 CDKN2A CEBPA DDIT3 DES FRS2
4 growth/size/body region MP:0005378 10.52 CDK4 CDKN2A CEBPA DDIT3 FRS2 IGF1R
5 homeostasis/metabolism MP:0005376 10.52 CD34 CDK4 CDKN2A CEBPA DDIT3 DES
6 embryo MP:0005380 10.45 CDK4 CDKN2A FRS2 IGF1R KIT MB
7 hematopoietic system MP:0005397 10.45 CD34 CDK4 CDKN2A CEBPA DDIT3 IGF1R
8 endocrine/exocrine gland MP:0005379 10.44 CDK4 CDKN2A CEBPA DDIT3 IGF1R KIT
9 mortality/aging MP:0010768 10.44 CDK4 CDKN2A CEBPA DES FRS2 IGF1R
10 immune system MP:0005387 10.43 CD34 CDK4 CDKN2A CEBPA DDIT3 IGF1R
11 integument MP:0010771 10.39 CD34 CDK4 CDKN2A CEBPA IGF1R KIT
12 liver/biliary system MP:0005370 10.37 CDK4 CDKN2A CEBPA DDIT3 IGF1R KIT
13 muscle MP:0005369 10.37 CDK4 CDKN2A CEBPA DES IGF1R KIT
14 digestive/alimentary MP:0005381 10.35 CDK4 CDKN2A CEBPA IGF1R KIT MDM2
15 neoplasm MP:0002006 10.35 CD34 CDK4 CDKN2A CEBPA DDIT3 IGF1R
16 nervous system MP:0003631 10.3 CDK4 CDKN2A DDIT3 FRS2 IGF1R KIT
17 craniofacial MP:0005382 10.27 CDK4 FRS2 IGF1R KIT MDM2 MET
18 adipose tissue MP:0005375 10.24 CEBPA DDIT3 IGF1R MYOG PPARG PTEN
19 hearing/vestibular/ear MP:0005377 10.19 DDIT3 FRS2 IGF1R KIT NF1 PPARG
20 limbs/digits/tail MP:0005371 10.19 FRS2 IGF1R KIT MDM2 MET NF1
21 normal MP:0002873 10.14 CDK4 CEBPA KIT MDM2 MET MYOG
22 no phenotypic analysis MP:0003012 10.09 CDKN2A CEBPA KIT MDM2 MET MYOG
23 renal/urinary system MP:0005367 10.06 CDK4 CEBPA KIT MDM2 MET NF1
24 reproductive system MP:0005389 10.03 CDK4 CDKN2A CEBPA IGF1R KIT MDM2
25 pigmentation MP:0001186 9.97 CDK4 CDKN2A KIT MDM2 NF1 PTEN
26 respiratory system MP:0005388 9.93 CDKN2A CEBPA IGF1R KIT MB MET
27 skeleton MP:0005390 9.7 CDK4 CDKN2A IGF1R KIT MDM2 MYOG
28 vision/eye MP:0005391 9.4 CDK4 CDKN2A CEBPA FRS2 KIT MET
Sources

Drugs & Therapeutics for Dedifferentiated Liposarcoma

About this section

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
2
Didanosine Approved Phase 2 69655-05-6 50599
3
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
4
Zidovudine Approved Phase 2 30516-87-1 35370
5
Stavudine Approved, Investigational Phase 2 3056-17-5 18283
6
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
7
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
8
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
9
nivolumab Approved Phase 2 946414-94-4
10
Ipilimumab Approved Phase 2 477202-00-9
11 Alkylating Agents Phase 2
12 Lamivudine, zidovudine drug combination Phase 2
13 Anti-HIV Agents Phase 2
14 Reverse Transcriptase Inhibitors Phase 2
15 Antimetabolites Phase 2
16 Anti-Infective Agents Phase 2
17 Anti-Retroviral Agents Phase 2
18 Antiviral Agents Phase 2
19 Immunosuppressive Agents Phase 2
20 Immunologic Factors Phase 2
21 Protein Kinase Inhibitors Phase 2
22 Antineoplastic Agents, Immunological Phase 2
23 Immunoglobulins Phase 2
24 Antibodies, Monoclonal Phase 2
25 Antibodies Phase 2
26
Efavirenz Approved, Investigational 154598-52-4 64139
27 Cytochrome P-450 Enzyme Inhibitors

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Active, not recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
2 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT03096912 Phase 2 Ribociclib
3 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
4 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
5 A Randomized Comparative Study of Combined Zidovudine-Lamivudine (3TC) vs. the Better of ddI Monotherapy vs. Zidovudine Plus Ddl in Symptomatic HIV-1 Infected Children Completed NCT00001066 Phase 2 Lamivudine;Zidovudine;Didanosine
6 A Phase II Randomized Study of the Virologic and Immunologic Effects of d4T vs Zidovudine Plus d4T vs Zidovudine Plus Ddl in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and Greater Than 12 Weeks Zidovudine Experience Completed NCT00001063 Phase 2 Stavudine;Zidovudine;Didanosine
7 Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Recruiting NCT03114527 Phase 2 Ribociclib;Everolimus
8 A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated and/or Dedifferentiated Liposarcoma Recruiting NCT04438824 Phase 2 INCMGA00012;Palbociclib
9 Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma Active, not recruiting NCT01913652 Phase 2 Cabazitaxel
10 Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Active, not recruiting NCT03307616 Phase 2
11 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma Active, not recruiting NCT02500797 Phase 2
12 Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma Active, not recruiting NCT02846987 Phase 2 Abemaciclib
13 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
14 A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Withdrawn NCT00969917 Phase 2 IPI-504
15 Correlation of DDLS Grading to OCT, HRT, and HVF Completed NCT00430287
16 Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Patients Completed NCT00116415 efavirenz; didanosine EC; lamivudine

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Sources

Genetic Tests for Dedifferentiated Liposarcoma

About this section
Sources

Anatomical Context for Dedifferentiated Liposarcoma

About this section

MalaCards organs/tissues related to Dedifferentiated Liposarcoma:

40
Colon, Breast, Lymph Node, Kidney, Liver, Pancreas, Spleen
Sources

Publications for Dedifferentiated Liposarcoma

About this section

Articles related to Dedifferentiated Liposarcoma:

(show top 50) (show all 715)
# Title Authors PMID Year
1
Well-differentiated and dedifferentiated liposarcomas. 61 54
19688222 2010
2
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. 61 54
19946100 2009
3
SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. 54 61
19454362 2009
4
Other targetable sarcomas. 61 54
19664496 2009
5
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. 54 61
18820664 2009
6
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. 61 54
18836421 2009
7
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 54 61
18500263 2008
8
Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. 61 54
18204431 2008
9
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. 54 61
17638873 2007
10
[Extragastrointestinal stromal tumors: a report of 4 cases]. 54 61
16472759 2006
11
alpha-fetoprotein expression in a dedifferentiated liposarcoma. 61 54
16489442 2006
12
Alterations of the RB1 gene in dedifferentiated liposarcoma. 54 61
15933756 2005
13
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 54 61
16160477 2005
14
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 54 61
12640106 2003
15
Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. 54 61
11480734 2001
16
Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. 54 61
11484509 2001
17
Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. 54 61
11518050 2001
18
Fibrohistiocytic differentiation in subcutaneous fatty tumors. Study of spindle cell, pleomorphic, myxoid, and atypical lipoma and dedifferentiated liposarcoma cases composed in part of CD34+ fibroblasts and FXIIIa+ histiocytes. 54 61
9331894 1997
19
Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. 61 54
9071997 1997
20
Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. 61
33206381 2021
21
Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. 61
32860002 2021
22
The Utility of Perilipin in Liposarcomas: PLIN1 Differentiates Round Cell Liposarcoma From Other Round Cell Sarcomas. 61
32205741 2021
23
A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. 61
33285287 2021
24
Concurrent minimal change disease and retroperitoneal liposarcoma successfully treated by tumor resection and steroid therapy. 61
32902814 2021
25
Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study. 61
33290314 2021
26
An oncologic emergency case of massive dedifferentiated liposarcoma of the small bowel mesentery. 61
33566308 2021
27
Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma. 61
33555519 2021
28
Metastatic dedifferentiated liposarcoma invading the pulmonary vein and left atrium: A transesophageal echocardiographic insight. 61
33538835 2021
29
DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma. 61
32815829 2021
30
Clinical features of multiply recurrent retroperitoneal liposarcoma: A single-center experience. 61
33191070 2021
31
Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. 61
32949334 2021
32
Primary dedifferentiated Liposarcoma of vagina: a first case report. 61
33422117 2021
33
Multi-omics analysis of copy number variations of RNA regulatory genes in soft tissue sarcoma. 61
33166590 2021
34
Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on 18F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma. 61
33505228 2021
35
The 2020 WHO Classification: What's New in Soft Tissue Tumor Pathology? 61
32796172 2021
36
PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas. 61
33468992 2021
37
Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy. 61
33084061 2021
38
Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma. 61
33111425 2021
39
Adjuvant radiotherapy in the treatment of dedifferentiated liposarcoma of the spermatic cord: a rare entity. 61
33419753 2021
40
The role of 18 F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study. 61
33444466 2021
41
Sustained activation of notch signaling maintains tumor-initiating cells in a murine model of liposarcoma. 61
32866607 2020
42
Well-Differentiated/Dedifferentiated Liposarcoma Arising in the Upper Aerodigestive Tract: 8 Cases Mimicking Non-adipocytic Lesions. 61
32410132 2020
43
[A Case of Primary Liposarcoma of Pancreas Difficult to Diagnose Preoperatively]. 61
33468873 2020
44
A Rapid and Cost-Effective Gene Expression Assay for the Diagnosis of Well-Differentiated and Dedifferentiated Liposarcomas. 61
33346147 2020
45
Dedifferentiated liposarcoma of the gallbladder. 61
32783326 2020
46
Synchronous Renal Dedifferentiated Liposarcoma and Retroperitoneal Well-Differentiated Liposarcoma: A Case Report With Literature Review. 61
33355009 2020
47
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. 61
33130422 2020
48
Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. 61
33287361 2020
49
What Are the Results of Resection of Localized Dedifferentiated Liposarcomas in the Extremities? 61
33112583 2020
50
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma. 61
32952659 2020
Sources

Variations for Dedifferentiated Liposarcoma

About this section
Sources

Expression for Dedifferentiated Liposarcoma

About this section
Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.
Sources

Pathways for Dedifferentiated Liposarcoma

About this section

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.84 TP53 STAT6 RB1 PTEN NF1 MET
2
GPCR Pathway 63
Show member pathways
 13.72 TP53 STAT6 RB1 MET MDM2 KIT
3
Developmental Biology 65
Show member pathways
 13.52 PPARG NF1 MYOG MET KIT FRS2
4
Akt Signaling 63
Show member pathways
 13.43 TP53 STAT6 PTEN MET MDM2 KIT
5
Cellular Senescence (REACTOME) 65
Show member pathways
 13.16 TP53 RB1 MDM2 HMGA2 CDKN2A CDK4
6
GAB1 signalosome 65
Show member pathways
 13.14 TP53 PTEN MET MDM2 KIT FRS2
7
Phospholipase-C Pathway 63
Show member pathways
 13.09 TP53 PTEN MET MDM2 KIT IGF1R
8
PI3K-Akt signaling pathway 36
Show member pathways
 13.02 TP53 RB1 PTEN MET MDM2 KIT
9
MAPK signaling pathway 36 1
12.81 TP53 NF1 MET KIT IGF1R DDIT3
10
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.77 TP53 PTEN MET MDM2 KIT FRS2
11
Gastric cancer 36
Show member pathways
 12.76 TP53 RB1 PTEN MET KIT IGF1R
12
Apoptosis Modulation and Signaling 1
Show member pathways
 12.73 TP53 MDM2 IGF1R DDIT3 CDKN2A
13
Endometrial cancer 36
Show member pathways
 12.7 TP53 RB1 PTEN PPARG MDM2 KIT
14
ErbB signaling pathway 36 1
Show member pathways
 12.65 TP53 PTEN NF1 MET MDM2 IGF1R
15
Mitotic G1-G1/S phases 65
Show member pathways
 12.6 TP53 RB1 MDM2 CDKN2A CDK4
16
MicroRNAs in cancer 36
12.58 TP53 PTEN MET MDM2 HMGA2 CDKN2A
17
Glioma 36
Show member pathways
 12.58 TP53 RB1 PTEN NF1 MET MDM2
18
Glucose / Energy Metabolism 4
12.57 PTEN PPARG MB IGF1R CEBPA
19
DNA Damage 4
12.54 TP53 RB1 MDM2 CDKN2A CDK4
20
Apoptosis Pathway 70
Show member pathways
 12.45 TP53 MET MDM2 IGF1R
21
Cell cycle 36 1
12.42 TP53 RB1 MDM2 CDKN2A CDK4
22
DNA Damage Response 1
Show member pathways
 12.42 TP53 RB1 PTEN MDM2 CDKN2A CDK4
23
Human T-cell leukemia virus 1 infection 36
12.38 TP53 RB1 PTEN CDKN2A CDK4
24
Development IGF-1 receptor signaling 23
Show member pathways
 12.38 TP53 STAT6 PTEN MET MDM2 IGF1R
25
Cyclins and Cell Cycle Regulation 63
Show member pathways
 12.37 TP53 RB1 CDKN2A CDK4
26
Proteoglycans in cancer 36
12.35 TP53 MET MDM2 IGF1R FRS2
27
Viral carcinogenesis 36
12.35 TP53 RB1 MDM2 CDKN2A CDK4
28
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.33 TP53 PTEN MDM2 IGF1R
30
p53 Signaling 63
Show member pathways
 12.3 TP53 RB1 PTEN MDM2 CDK4
31
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.29 TP53 RB1 MET KIT IGF1R
32
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.29 TP53 RB1 PTEN MET MDM2 IGF1R
33
Cellular senescence (KEGG) 36
12.19 TP53 RB1 PTEN MDM2 CDKN2A CDK4
34
Integrated Breast Cancer Pathway 1
12.17 TP53 RB1 PTEN NF1 MDM2 CDK4
35
Tyrosine Kinases / Adaptors 4
12.16 MET KIT IGF1R FRS2
36
Pathways in cancer 36
12.13 TP53 STAT6 RB1 PTEN PPARG MET
37
Direct p53 effectors 1
12.12 TP53 RB1 PTEN MET MDM2
38
Adipogenesis 1
12.12 STAT6 RB1 PPARG DDIT3 CEBPA
39
Transcriptional misregulation in cancer 36
12.04 TP53 PPARG MET MDM2 IGF1R HMGA2
40
DNA Damage Response (only ATM dependent) 1
12.03 TP53 PTEN MDM2 CDKN2A
41
Small cell lung cancer 36
11.93 TP53 RB1 PTEN CDK4
42
Senescence and Autophagy in Cancer 1
11.91 TP53 RB1 PTEN MDM2 IGF1R CDKN2A
43
Retinoblastoma (RB) in Cancer 1
11.9 TP53 RB1 MDM2 CDK4
44
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.82 PPARG MYOG KIT DES CEBPA CD34
45
Bladder cancer 36 1
11.81 TP53 RB1 MDM2 CDKN2A CDK4
46
C-MYB transcription factor network 1
11.8 KIT CEBPA CD34
47
Central carbon metabolism in cancer 36
11.77 TP53 PTEN MET KIT
48
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.76 TP53 MDM2 CDKN2A
49
Platinum drug resistance 36
11.76 TP53 MDM2 CDKN2A
50
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.73 RB1 IGF1R CDK4
Sources

GO Terms for Dedifferentiated Liposarcoma

About this section

Cellular components related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.28 TP53 STAT6 RB1 PTEN PPARG NF1
2 nucleoplasm GO:0005654 9.93 TP53 STAT6 RB1 PTEN PPARG MYOG
3 receptor complex GO:0043235 9.67 PPARG MET KIT IGF1R
4 chromatin GO:0000785 9.61 TP53 STAT6 RB1 PPARG MYOG HMGA2
5 RNA polymerase II transcription factor complex GO:0090575 9.58 PPARG DDIT3 CEBPA
6 protein-DNA complex GO:0032993 9.5 MYOG HMGA2 DDIT3
7 senescence-associated heterochromatin focus GO:0035985 9.26 HMGA2 CDKN2A
8 transcription factor complex GO:0005667 9.1 TP53 RB1 MYOG DDIT3 CEBPA CDK4

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.22 TP53 STAT6 RB1 PPARG MYOG HMGA2
2 regulation of transcription by RNA polymerase II GO:0006357 10.19 TP53 STAT6 RB1 PPARG MYOG MDM2
3 apoptotic process GO:0006915 10.1 TP53 RB1 PTEN MDM2 DDIT3 CDKN2A
4 positive regulation of transcription, DNA-templated GO:0045893 10.05 TP53 PPARG MYOG HMGA2 DDIT3 CEBPA
5 cell cycle GO:0007049 10.02 TP53 RB1 MYOG HMGA2 DDIT3 CDKN2A
6 negative regulation of transcription by RNA polymerase II GO:0000122 10.01 TP53 STAT6 RB1 PPARG MDM2 HMGA2
7 response to drug GO:0042493 10 TP53 PTEN PPARG MDM2 CDK4
8 positive regulation of protein kinase B signaling GO:0051897 9.94 MET KIT IGF1R FRS2
9 regulation of cell cycle GO:0051726 9.92 TP53 RB1 PTEN CDK4
10 heart development GO:0007507 9.92 TP53 PTEN PPARG NF1 MDM2
11 cell cycle arrest GO:0007050 9.91 TP53 RB1 DDIT3 CDKN2A
12 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.89 MET KIT IGF1R FRS2
13 regulation of cell proliferation GO:0042127 9.89 TP53 STAT6 KIT CEBPA CDK4
14 negative regulation of cell growth GO:0030308 9.87 TP53 RB1 PPARG CDKN2A
15 positive regulation of apoptotic process GO:0043065 9.87 TP53 PTEN PPARG NF1 HMGA2 CDKN2A
16 negative regulation of transcription, DNA-templated GO:0045892 9.86 TP53 RB1 PPARG MDM2 HMGA2 DDIT3
17 response to organic substance GO:0010033 9.85 PTEN PPARG CDK4
18 liver development GO:0001889 9.85 NF1 MET CEBPA
19 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 PTEN PPARG KIT DDIT3
20 positive regulation of kinase activity GO:0033674 9.83 MET KIT IGF1R
21 positive regulation of neuron apoptotic process GO:0043525 9.81 TP53 NF1 DDIT3
22 phosphatidylinositol 3-kinase signaling GO:0014065 9.79 PTEN NF1 IGF1R
23 Ras protein signal transduction GO:0007265 9.76 TP53 RB1 NF1 CDKN2A
24 positive regulation of gene expression GO:0010628 9.76 TP53 PTEN MDM2 KIT HMGA2 CEBPA
25 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.73 PTEN CEBPA CDKN2A
26 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.73 RB1 PTEN CDKN2A CDK4
27 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.67 TP53 DDIT3
28 amyloid fibril formation GO:1990000 9.67 MDM2 CDKN2A
29 positive regulation of cell cycle arrest GO:0071158 9.67 TP53 MYOG HMGA2 CDKN2A
30 ER overload response GO:0006983 9.66 TP53 DDIT3
31 forebrain morphogenesis GO:0048853 9.65 PTEN NF1
32 somatic stem cell division GO:0048103 9.65 KIT CDKN2A
33 cellular response to UV-C GO:0071494 9.65 TP53 MDM2
34 negative regulation of neuroblast proliferation GO:0007406 9.64 TP53 NF1
35 cellular response to actinomycin D GO:0072717 9.58 TP53 MDM2
36 senescence-associated heterochromatin focus assembly GO:0035986 9.58 HMGA2 CDKN2A
37 negative regulation of cell proliferation GO:0008285 9.56 TP53 RB1 PTEN PPARG NF1 MYOG
38 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 TP53 STAT6 RB1 PPARG MYOG MET

Molecular functions related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.5 TP53 STAT6 RB1 PTEN PPARG NF1
2 DNA binding GO:0003677 10.13 TP53 STAT6 RB1 PPARG MYOG HMGA2
3 DNA-binding transcription factor activity GO:0003700 9.88 TP53 STAT6 PPARG MYOG DDIT3 CEBPA
4 identical protein binding GO:0042802 9.85 TP53 STAT6 RB1 PTEN PPARG MET
5 enzyme binding GO:0019899 9.83 TP53 RB1 PTEN PPARG MDM2
6 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.8 TP53 STAT6 MYOG MDM2 DDIT3 CEBPA
7 transcription regulatory region sequence-specific DNA binding GO:0000976 9.77 TP53 PPARG HMGA2 DDIT3 CEBPA
8 p53 binding GO:0002039 9.67 TP53 MDM2 CDKN2A
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 MET KIT IGF1R
10 protein phosphatase binding GO:0019903 9.56 TP53 STAT6 PPARG MET
11 MDM2/MDM4 family protein binding GO:0097371 9.51 TP53 CDKN2A
12 disordered domain specific binding GO:0097718 9.26 TP53 RB1 MDM2 CDKN2A
13 transcription factor binding GO:0008134 9.23 TP53 RB1 PPARG HMGA2 DDIT3 CEBPA
Sources

Sources for Dedifferentiated Liposarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....